vs

Side-by-side financial comparison of ASTRONICS CORP (ATRO) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.

ASTRONICS CORP is the larger business by last-quarter revenue ($240.1M vs $168.4M, roughly 1.4× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 15.1%). Over the past eight quarters, ASTRONICS CORP's revenue compounded faster (13.9% CAGR vs 10.6%).

Astronics Corporation is an American aerospace electronics corporation founded in 1968, headquartered in East Aurora, New York. It is traded on NASDAQ as Nasdaq: ATRO. It is known for lighting and electronics integrations on military, commercial, and business aircraft and semiconductor test systems.

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

ATRO vs ESPR — Head-to-Head

Bigger by revenue
ATRO
ATRO
1.4× larger
ATRO
$240.1M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+128.6% gap
ESPR
143.7%
15.1%
ATRO
Faster 2-yr revenue CAGR
ATRO
ATRO
Annualised
ATRO
13.9%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ATRO
ATRO
ESPR
ESPR
Revenue
$240.1M
$168.4M
Net Profit
Gross Margin
33.3%
Operating Margin
14.8%
50.6%
Net Margin
Revenue YoY
15.1%
143.7%
Net Profit YoY
EPS (diluted)
$0.82
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATRO
ATRO
ESPR
ESPR
Q4 25
$240.1M
$168.4M
Q3 25
$211.4M
$87.3M
Q2 25
$204.7M
$82.4M
Q1 25
$205.9M
$65.0M
Q4 24
$208.5M
$69.1M
Q3 24
$203.7M
$51.6M
Q2 24
$198.1M
$73.8M
Q1 24
$185.1M
$137.7M
Net Profit
ATRO
ATRO
ESPR
ESPR
Q4 25
Q3 25
$-11.1M
$-31.3M
Q2 25
$1.3M
$-12.7M
Q1 25
$9.5M
$-40.5M
Q4 24
Q3 24
$-11.7M
$-29.5M
Q2 24
$1.5M
$-61.9M
Q1 24
$-3.2M
$61.0M
Gross Margin
ATRO
ATRO
ESPR
ESPR
Q4 25
33.3%
Q3 25
30.5%
Q2 25
25.8%
Q1 25
29.5%
Q4 24
29.8%
Q3 24
27.1%
Q2 24
28.0%
Q1 24
25.7%
Operating Margin
ATRO
ATRO
ESPR
ESPR
Q4 25
14.8%
50.6%
Q3 25
10.9%
-11.4%
Q2 25
2.3%
8.6%
Q1 25
6.4%
-34.0%
Q4 24
4.3%
-6.4%
Q3 24
4.1%
-31.0%
Q2 24
3.8%
3.5%
Q1 24
0.9%
52.5%
Net Margin
ATRO
ATRO
ESPR
ESPR
Q4 25
Q3 25
-5.2%
-35.9%
Q2 25
0.6%
-15.4%
Q1 25
4.6%
-62.2%
Q4 24
Q3 24
-5.8%
-57.2%
Q2 24
0.8%
-83.9%
Q1 24
-1.7%
44.3%
EPS (diluted)
ATRO
ATRO
ESPR
ESPR
Q4 25
$0.82
$0.32
Q3 25
$-0.31
$-0.16
Q2 25
$0.04
$-0.06
Q1 25
$0.26
$-0.21
Q4 24
$-0.07
$-0.14
Q3 24
$-0.34
$-0.15
Q2 24
$0.04
$-0.33
Q1 24
$-0.09
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATRO
ATRO
ESPR
ESPR
Cash + ST InvestmentsLiquidity on hand
$18.2M
$167.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$140.1M
$-302.0M
Total Assets
$706.7M
$465.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATRO
ATRO
ESPR
ESPR
Q4 25
$18.2M
$167.9M
Q3 25
$13.5M
$92.4M
Q2 25
$13.5M
$86.1M
Q1 25
$24.8M
$114.6M
Q4 24
$9.3M
$144.8M
Q3 24
$5.2M
$144.7M
Q2 24
$2.9M
$189.3M
Q1 24
$5.3M
$226.6M
Stockholders' Equity
ATRO
ATRO
ESPR
ESPR
Q4 25
$140.1M
$-302.0M
Q3 25
$108.9M
$-451.4M
Q2 25
$271.6M
$-433.5M
Q1 25
$266.8M
$-426.2M
Q4 24
$256.1M
$-388.7M
Q3 24
$249.2M
$-370.2M
Q2 24
$257.9M
$-344.2M
Q1 24
$251.7M
$-294.3M
Total Assets
ATRO
ATRO
ESPR
ESPR
Q4 25
$706.7M
$465.9M
Q3 25
$682.2M
$364.0M
Q2 25
$646.7M
$347.1M
Q1 25
$662.2M
$324.0M
Q4 24
$648.8M
$343.8M
Q3 24
$651.6M
$314.1M
Q2 24
$644.9M
$352.3M
Q1 24
$630.0M
$373.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATRO
ATRO
ESPR
ESPR
Operating Cash FlowLast quarter
$27.6M
$45.2M
Free Cash FlowOCF − Capex
$15.8M
FCF MarginFCF / Revenue
6.6%
Capex IntensityCapex / Revenue
4.9%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$43.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATRO
ATRO
ESPR
ESPR
Q4 25
$27.6M
$45.2M
Q3 25
$34.2M
$-4.3M
Q2 25
$-7.6M
$-31.4M
Q1 25
$20.6M
$-22.6M
Q4 24
$26.4M
$-35.0M
Q3 24
$8.4M
$-35.3M
Q2 24
$-6.3M
$-7.2M
Q1 24
$2.0M
$53.8M
Free Cash Flow
ATRO
ATRO
ESPR
ESPR
Q4 25
$15.8M
Q3 25
$21.0M
Q2 25
$-12.2M
Q1 25
$18.5M
Q4 24
$23.2M
Q3 24
$6.5M
$-35.5M
Q2 24
$-8.1M
$-7.3M
Q1 24
$439.0K
$53.8M
FCF Margin
ATRO
ATRO
ESPR
ESPR
Q4 25
6.6%
Q3 25
9.9%
Q2 25
-6.0%
Q1 25
9.0%
Q4 24
11.1%
Q3 24
3.2%
-68.7%
Q2 24
-4.1%
-9.9%
Q1 24
0.2%
39.0%
Capex Intensity
ATRO
ATRO
ESPR
ESPR
Q4 25
4.9%
0.0%
Q3 25
6.2%
0.0%
Q2 25
2.2%
0.0%
Q1 25
1.0%
0.0%
Q4 24
1.5%
0.0%
Q3 24
0.9%
0.3%
Q2 24
0.9%
0.1%
Q1 24
0.9%
0.1%
Cash Conversion
ATRO
ATRO
ESPR
ESPR
Q4 25
Q3 25
Q2 25
-5.81×
Q1 25
2.17×
Q4 24
Q3 24
Q2 24
-4.08×
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATRO
ATRO

Product Line Electrical Power And Motion$113.8M47%
Product Line Avionics$32.0M13%
Military Aircraft$28.0M12%
General Aviation$22.3M9%
Government And Defense$20.5M9%
Product Line Systems Certification$13.2M6%
Product Line Structures$3.7M2%
Product Line Other$2.3M1%

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

Related Comparisons